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The activation of type I IFN signaling is a major component of host defense against viral infection, but it is
not typically associated with immune responses to extracellular bacterial pathogens. Using mouse and human
airway epithelial cells, we have demonstrated that Staphylococcus aureus activates type I IFN signaling, which
contributes to its virulence as a respiratory pathogen. This response was dependent on the expression of protein A and, more specifically, the Xr domain, a short sequence–repeat region encoded by DNA that consists of
repeated 24-bp sequences that are the basis of an internationally used epidemiological typing scheme. Protein
A was endocytosed by airway epithelial cells and subsequently induced IFN-β expression, JAK-STAT signaling,
and IL-6 production. Mice lacking IFN-α/β receptor 1 (IFNAR-deficient mice), which are incapable of responding to type I IFNs, were substantially protected against lethal S. aureus pneumonia compared with wild-type
control mice. The profound immunological consequences of IFN-β signaling, particularly in the lung, may
help to explain the conservation of multiple copies of the Xr domain of protein A in S. aureus strains and the
importance of protein A as a virulence factor in the pathogenesis of staphylococcal pneumonia.
Introduction
Staphylococcus aureus has reemerged as a major human pathogen,
and in 2005, infection due to methicillin-resistant (MRSA) strains
alone caused more than 18,000 deaths in the US, many acquired
in the community by normal hosts. Staphylococcal pneumonia
contributed to more than 75% of these deaths (1). Such invasive
infections indicate successful bacterial exploitation of the immune
system. While S. aureus has many gene products that directly interact with diverse immune effectors, exactly how such devastating
infections occur is not entirely clear. Local production of cytotoxin,
such as the α-hemolysin (2), Panton-Valentine leukocidin (PVL) (3),
and phenol soluble modulins (4), clearly contributes to pathology.
However, none of these are uniformly expressed by these virulent
isolates of S. aureus (5), suggesting that additional virulence factors
must be important in the pathogenesis of these infections.
Staphylococcal protein A (SpA) is a conserved surface component
of all S. aureus strains, consisting of an N-terminal IgG-binding
domain, an Xr or short sequence–repeat region (SSR) encoded by
variable numbers of 24-bp repeated DNA sequences, and a C-terminal anchor to the bacterial cell wall (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/
JCI35879DS1) (6). The amino terminus of SpA, the IgG-binding
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domain, activates tumor necrosis factor receptor 1 (TNFR1) (7) and
EGFR (8), contributing substantially to the pathology induced by
the inflammatory response evoked by S. aureus, and the SpA-TNFR1
interaction has been shown to be essential in the pathogenesis of
staphylococcal pneumonia (7). The Xr region provides the basis of
the spa typing system and is generated by deletion, duplication, and
point mutation of the repeated DNA sequences (9). This provides
sufficient diversity to differentiate strains involved in clinical outbreaks of infection from all over the world (10). However, despite
their widespread conservation, the function of these repeated
sequences has been entirely unclear.
To explore the biological role of the Xr domain of SpA, we translated the DNA sequences of the repeats present in the most frequent spa types and found that they encode highly conserved peptides (Supplemental Figure 1B) with homology to LMP1 of EBV,
the major oncoprotein of EBV and a potent activator of type I IFN
signaling (11). The type I IFN cascade is a major immune effector
critical for the systemic response to viral infection (12) and the
coordination of innate and adaptive immune responses (13). Mice
lacking components of the type I IFN signaling system (trif –/– and
Ifnar–/–, where TRIF indicates TIR-domain-containing adapterinducing interferon-β and IFNAR indicates IFN-α/β receptor 1)
are highly susceptible to viral infection but are afforded significant
protection from endotoxin-mediated death (14, 15). Similarly, type
I IFN production has been shown to increase host susceptibility to
the Gram-positive obligate intracellular organism Listeria monocytogenes (16). This cascade has been associated with both pro- and
antiinflammatory signaling through the activation of STAT1,
STAT2, and STAT3 (17). In a number of inflammatory conditions,
IFN-β downregulates many genes, including matrix metalloproteinases, chemokines, and adhesion molecules (18). While type I
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Figure 1
S. aureus strain USA300 induces type I IFN signaling in airway epithelial cells that is dependent on the expression of protein A. (A) Primary
mouse airway epithelial cells were incubated with S. aureus USA300 or a SpA deletion mutant, and induction of IFN-β, Mx-1, IL-6, LIF, and PKR
was detected by real-time PCR. Data are represented as fold increases over unstimulated controls and are representative of 3 independent
experiments. *P < 0.05 as compared with the spa-null strain, Student’s t test. Error bars represent standard deviations. (B) p-STAT1, p-STAT2,
and p-STAT3 were detected by immunoblot in primary airway epithelial cell cultures treated with USA300 (+) or spa-null (–). Corresponding total
STATs are shown for loading controls.

IFN signaling can be activated by diverse microbial signals, a typical cascade involves TLR-mediated recognition of an intracellular
microbial component, IRF3- and IRF7-mediated transcription of
IFN-β, and, through an autocrine pathway, ligation of the IFN-α/β
receptor IFNAR, which in turn stimulates tyrosine kinase 2 (Tyk2)
and the JAK-STAT cascade, resulting in cell type–dependent
immune responses, including IL-6 production (19).
Having previously found that SpA readily activates IL-6 production in airway cells (20), we postulated that S. aureus activates the
type I IFN cascade and that SpA is involved. As the major mediators
of the type I IFN cascade are well known, we focused on what we
believe are the novel aspects of this hypothesis: how extracellular
Gram-positive bacteria could induce signaling that has been previously associated with intracellular viral infection or mediated by
LPS and TLR4 (15, 21, 22). We demonstrate that S. aureus, through
the Xr domain of SpA, activates known components of the type
I IFN cascade and that this contributes to the virulence of the
organism as a respiratory pathogen.
Results
S. aureus USA300 activates type I IFN signaling in airway cells. S. aureus
strain USA300 is a community-acquired methicillin-resistant
strain now epidemic in the US (1). We tested the ability of this
strain to induce type I IFN signaling in murine airway epithelial
cells in primary culture and used a spa-null mutant to determine
the contribution of SpA in this process. A sharp increase in IFN-β
transcription was detected following exposure to USA300 but
not the spa mutant (100-fold at 2 hours and >400 fold at 4 hours)
(Figure 1A). Induction of IFN-α family members was not detected.
Production of IFN-β–dependent gene products was also observed:
USA300 induced a 7-fold increase in Mx-1, a prototypical type
I IFN antiviral effector, a 130-fold increase in IL-6, and a 4-fold


increase in Lif, a gene product that is important in host defense in
the lung specifically (23). Induction of these IFN-dependent gene
products was significantly attenuated in the absence of SpA (Figure 1A). Induction of PKR transcription, important in the induction of apoptosis and sensitization of macrophages against the
effects of LPS (24), was not observed (Figure 1A).
Production of IFN-β is followed by an autocrine pathway consisting of activation of the common IFN-α/β receptor (IFNAR),
phosphorylation of the transcription factors STAT1, STAT2, and
STAT3 by JAK family kinases, and expression of more than 300
type I IFN-dependent genes (25). We compared the activation of
this cascade in murine airway cells in response to USA300 with
that in response to a spa mutant. Both STAT1 and STAT2 became
phosphorylated after exposure to USA300 (required for induction
of IFN-β–dependent gene products such as Mx-1), coincident with
IFN-β production. This phosphorylation was less pronounced in
cells exposed to the spa-null mutant. Tyrosine phosphorylation
of STAT3 was induced by both strains, indicating the presence of
SpA-independent signaling mechanisms (Figure 1B). These data
indicate that S. aureus potently induces the type I IFN cascade in
airway epithelial cells and that much of this response is dependent on expression of SpA.
Ifnar–/– mice are protected from S. aureus–associated mortality. The
requirement for type I IFN signaling in the resolution of viral respiratory infections has been well documented (12). However trif–/–
and Ifnar–/– mice are protected from the lethal affects of endotoxin
(14, 15). To determine whether staphylococcal activation of type I
IFN signaling has similar negative consequences, WT (129/SvEv)
and Ifnar–/– mice were intranasally infected with S. aureus USA300.
The Ifnar–/– mice were protected from lethal pneumonia with
significantly reduced mortality, 10% as compared with 80% seen
in the WT animals (P = 0.0055 by Fisher’s exact test; Figure 2A).
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Figure 2
Type I IFN signaling increases susceptibility to staphylococcal respiratory infection. Adult WT or Ifnar–/– mice were intranasally infected with (A)
5 × 108 CFUs of S. aureus USA300 and mortality determined at 24 hours. *P = 0.0055, Fisher’s exact test; n = 10 mice per group. Mice were
infected with 5 × 107 CFUs of S. aureus USA300 and at 4 and 24 hours after infection (B), bacterial loads were determined in lungs and spleens
and lung suspensions and cells obtained by BAL fluid stained and analyzed by flow cytometry to enumerate (C) CD45+Gr1+ PMNs and (D)
CD11c+CD11b+CD45+ DCs. Data are represented as percentage of total CD45 population. (E) TNF-α and IL-6 were detected in BAL fluid and
blood by ELISA. Each point represents 1 animal; horizontal lines represent median values.

Using a 10-fold lower sublethal inoculum, we were able to compare
the immune responses to USA300 in mice. There were no differences in either the levels of infection (Figure 2B) or the numbers of
polymorphonuclear leukocytes (PMNs) recruited into the lungs of

the Ifnar–/– and WT mice at either 4 or 24 hours after inoculation
(Figure 2C). Although there was slightly more bacteremia found at
4 hours in the Ifnar–/– animals (Figure 2B), this was less than a log
difference, which was gone at 24 hours.
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Figure 3
SpA is internalized and induces type 1 IFN signaling in airway epithelial cells. (A–E) Airway cells were incubated with SpA or SpA Xr and (A)
internalization monitored by flow cytometry (ΔMFI, change in mean fluorescence intensity) or (B) by confocal microscopy for SpA (green) and
transferrin (red) at 1 hour (original magnification, ×80). (C) SpA-induced IFN-β production was measured at 2 hours by real-time PCR in the
presence of Dynasore (Dyn), (D) in response to transfection of an SpA Xr plasmid (Xr) or empty vector (CV), and (E) in the presence of 50 μg/ml
polymixin B. (F) STAT1 and STAT3 phosphorylation in response to SpA (S) or LPS (L) after 1 and 2 hours was monitored in murine nasal epithelial cells from WT or trif–/– mice. (G) STAT1 and STAT3 phosphorylation was monitored in airway cells in response to SpA Xr (30 min., n = 2;
60 and 120 min., n = 3), in the presence of Dyn (n = 3), pan-JAK inhibitor (Pan, n = 3), JAK2 inhibitor (JAK2, n = 3), or neutralizing antibody to
IFN-β (n = 2). Thin vertical lines between bands indicate data spliced together from original blot. Red arrows indicate that the same bands from
the 120 min. Xr treatment were used as the control for pan-JAK and JAK2 inhibitor treatments. U, M, or Unstim. indicates unstimulated control.
Unless otherwise indicated, data shows mean values of triplicate samples from 1 representative experiment out of 3, and error bars indicate
standard deviations. *P < 0.001; **P < 0.05.

The Ifnar–/– mice had significantly more CD11c+ DCs both in
lung homogenates and bronchoalveolar lavage (BAL) fluid, which
persisted from 4 to 24 hours (Figure 2D). At the same time points,
the Ifnar–/– mice had significantly less TNF-α, and a trend toward
less IL-6 in the BAL fluid compared with the WT animals (Figure
2E). Systemic levels of TNF-α were minimal in both groups and at
least an order of magnitude less than those detected in the BAL


fluid (Figure 2E). These findings suggest that the major impact
of type I IFN signaling in response to S. aureus is in the lung and
involves the DC population and immune regulation.
The Xr domain of SpA activates IFN-β signaling. SpA has already been
shown to be critical in the pathogenesis of pneumonia in a mouse
model of infection (7). We next analyzed the contribution of each
of the SpA subdomains in the activation of type I IFN responses
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Figure 4
SpA Xr induces IFN-β– and STAT3-dependent IL-6 production. (A) Airway epithelial cells in primary culture were stimulated with SpA Xr for the
times indicated or for 2 hours in the absence or presence of dynasore, and IL-6 induction was detected by real-time PCR (black bars, left y axis)
or ELISA (white bars, right y axis). Untreated cells or cells stimulated with SpA Xr were incubated with IFN-β–neutralizing antibody, and IL-6
induction was measured by real-time PCR. IL-6 mRNA production is expressed as the fold induction compared with that of unstimulated cells.
(B) Airway epithelial cells from WT or Stat1–/– mice were stimulated with SpA Xr in the absence (control) or presence of the inhibitors indicated,
and IL-6 production was measured by real-time PCR. IL-6 induction is expressed as a percentage of that induced by SpA Xr in cells from WT
mice. (A and B) Data represent the mean and SD of 3 wells from 1 representative experiment out of 3. *P < 0.05; **P < 0.001, Student’s t test
performed on the raw data. Immunoblots demonstrating phosphorylation of STAT3 in airway cells from Stat1–/– mice and inhibition in the presence of STAT3 inhibitor are shown in B.

in airway epithelial cells. The domains of SpA were subcloned to
determine whether the Xr domain is both necessary and sufficient
to activate the type I IFN response: namely, endocytosis of the
ligand, IFN-β transcription, and JAK-STAT activation (Figure 3).
To determine whether SpA is endocytosed, we incubated fluorescently labeled full-length SpA or a construct consisting of the
Xr domain from strain Newman (which is virtually identical to the
SpA of USA300) with human airway epithelial cells in primary culture and cell lines; after repeated washing and trypsin treatment
to remove surface-associated SpA, we assayed for intracellular SpA
(Figure 3A). Substantial internalization was detected by 1 hour of
incubation and was significantly inhibited in cells maintained at
4°C or treated with the dynamin inhibitor dynasore (26), suggesting an endocytic process. Confocal imaging was consistent with
accumulation of SpA in endosomes, as it colocalized extensively
with transferrin (Figure 3B). Translocation of internalized SpA to
the cytosol was assessed by incubating airway epithelial cells with
a SpA–β-lactamase fusion protein and determining cytosolic β-lactamase activity using a previously described reporter system (27).
SpA did not translocate from the vesicles into the cytosol over the
period of time studied (30 minutes to 4 hours) (data not shown).
Incubation of airway cells with SpA Xr for 2 hours induced IFN-β
transcription; this induction of IFN-β transcription in response to
SpA Xr was significantly blocked by dynamin inhibition (Figure
3C). Since these constructs were synthesized as overexpressed proteins in Escherichia coli, several control experiments were performed
to exclude the possibility that contaminating LPS was affecting
our experiments. As one control, we transfected airway cells with
a plasmid expressing SpA Xr or a vector control and documented

a 10-fold increase in IFN-β mRNA production as compared with
that induced by the empty vector (Figure 3D). In addition, the
recombinant Xr protein was pretreated with polymyxin B, which
blocked LPS-induced IFN-β and Mx-1 production but not that
stimulated by SpA Xr (Figure 3E).
The adaptor protein TRIF has been shown to be essential in
coupling pattern recognition receptors to IFN-β signaling. We
predicted that SpA-mediated activation of the pathway would be
similarly TRIF dependent. STAT1 phosphorylation in response to
either LPS or SpA was not observed in epithelial cells from trif –/–
mice as compared with those from the WT controls (Figure 3F).
STAT3 phosphorylation was only partially reduced in these animals, indicating that there are non-TRIF and non–IFN-β–dependent pathways that elicit STAT3 activation. Thus, it appears that
major components of the IFN-β pathway are activated both by LPS
and SpA, although the specific receptor(s) and adaptor proteins
remain to be identified.
Following IFN-β production, IFNAR was stimulated through
an autocrine pathway, activating JAK-STAT signaling to initiate
gene expression, which we monitored as STAT phosphorylation
by the epithelial cells (28). Human airway epithelial cells incubated with the SpA Xr domain exhibited dynamin-dependent
tyrosine phosphorylation of STAT1 and STAT3, mediated by
activation of JAK1 or Tyk2 but not JAK2 (Figure 3G), although
considerable amounts of constitutive phospho-STAT3 were present in unstimulated cells. Anti–IFN-β inhibited STAT1 but not
STAT3 phosphorylation (consistent with the signaling through
the gp130 receptors that utilize STAT3). STAT3 phosphorylation
(Ser727) was detected in cells transfected with a vector encoding
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Figure 5
SpA Xr activates STAT1/3 in vivo. (A) C57BL/6 mice were intranasally inoculated with SpA Xr, S. aureus, or PBS (control). 4 hours later, p-STAT1
(Tyr701), p-STAT3 (Tyr705), and β-actin were detected in lung lysates by immunoblot. Data from 2 representative mice out of 6 are shown for
both left quadrants and bottom right quadrant. Data from 2 representative mice out of 3 are shown for top right quadrant. The thin vertical line
between bands within a group indicate data spliced from the original blot. (B) IL-6 mRNA in the lung of SpA Xr–treated mice was detected by
real-time PCR, and the percentage of PMNs among total leukocytes in the lung was determined by flow cytometry following intranasal inoculation
of SpA Xr in untreated or JAK inhibitor–treated mice (Inh). Each dot represents an individual mouse, and horizontal lines show the median value
in each group. (C) IL-6 mRNA in the lung of S. aureus–infected mice was detected by real-time PCR. The median values of the percentage of
PMNs corresponding to those mice are shown.

full-length SpA or the Xr domain but not in airway cells expressing the SpA N terminus, indicating specificity for the Xr domain
(Supplemental Figure 2A).
IL-6 production is a major product of JAK-STAT signaling, and
epithelial IL-6 production contributes substantially to the pathophysiology associated with staphylococcal infection. Cells in primary culture produced both IL-6 mRNA and protein in response
to the Xr domain of SpA in a dynamin-dependent fashion, which
was blocked by exposure to anti–IFN-β (Figure 4A). Cells transfected with SpA Xr also produced IL-6 (Supplemental Figure 2B).
The involvement of JAK-STAT signaling in IL-6 production was
documented by monitoring responses in primary airway cells
from Stat1–/– mice or WT primary mouse cells treated with a
STAT3 inhibitor (Figure 4B). The Stat1–/– cells and those treated
with the STAT3 inhibitor did not produce IL-6 mRNA in response
to Xr exposure (Figure 4B). STAT3 phosphorylation was intact
in cells from the Stat1–/– animals in response to SpA Xr but substantially diminished in animals treated with the STAT3 inhibitor (Figure 4B). These experiments indicate that both STAT1 and
STAT3 are phosphorylated in response to SpA Xr and that both
contribute to the production of IL-6.
To further document that IFN-β signaling occurs in vivo in
response to staphylococcal infection, we demonstrated the phosphorylation of STAT1 and STAT3 in lung lysates from mice intranasally inoculated with either S. aureus strain Newman or with
the SpA Xr peptide alone (Figure 5A). Phosphorylation of STAT3
at Ser727 was also activated in vivo in mice infected with WT
S. aureus but not a protein A–null mutant (Supplemental Figure 3).
IL-6 mRNA was significantly increased in the SpA Xr–treated mice


and correlated with recruitment of PMNs into the lung. Both IL-6
mRNA and PMNs were decreased in mice treated with the panJAK inhibitor (Figure 5B). Mice treated with JAK inhibitor prior
to and during S. aureus infection had much less IL-6 production
than vehicle-treated animals (Figure 5C). The JAK inhibitor also
appeared to affect bacterial clearance and PMN recruitment, but
the effects were not statistically significant (Figure 5C).
Discussion
These studies indicate that extracellular Gram-positive bacteria
activate the type I IFN cascade effectively and that this contributes
to the morbidity and mortality associated with S. aureus respiratory infection. Protein A, already established as a major virulence
factor in the pathogenesis of pneumonia by virtue of its ability to
activate TNF signaling (7), also appears to be critical in the activation of IFN-β. It has been previously shown that protein A induces
type I IFN in lymphocytes (29). The Xr domain of SpA, which
consists of multiple 24-bp repeats of highly conserved peptides,
appears to be both necessary and sufficient for IFN-β activation
in airway epithelial cells. As protein A is abundantly shed from the
surface of growing staphylococci, it seems highly plausible that
this protein, even in the absence of intact organisms, is sufficient
to activate the epithelial mucosa. This is of particular importance
in the lung, where resident alveolar macrophages do not produce
bioactive IFN-β (30). Note that the induction of IFN-β is in addition to other SpA functions, such as IgG-Fc binding that thwarts
opsonization, binding to von Willebrand factor (31), and activation of TNFR1 and EGFR, all of which have been mapped to the
N-terminal IgG-binding region (8).
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Many details of the SpA-activated IFN-β signaling cascade
remain to be defined. While we demonstrate dynamin-dependent
endocytosis of SpA and the involvement of the TRIF adaptor, the
specific intracellular receptor, perhaps a TLR, remains to be identified. The downstream components of a typical IFN-β cascade previously shown to be activated by LPS are similarly stimulated by
S. aureus. Whereas STAT3 activation seems to be independent of
the cascade initiated by IFN-β, it is required for the downstream
effects of IFN-β–induced STAT1, such as IL-6 production.
Type I IFN signaling appears to have an important role in the
pathogenesis of staphylococcal pneumonia: Ifnar–/– mice had dramatically increased survival as compared with WT mice infected
with S. aureus USA300. As has been shown in murine models of
respiratory viral infection, potent type I IFN stimulation causes
significant loss of CD11c+ cells from the lung and appears to have
an important role in immunoregulation in the airways (32, 33).
The WT mice had significantly more TNF-α in their airways than
Ifnar–/– mice, and we have previously demonstrated that TNF-α
signaling is associated with substantial pulmonary pathology in
response to S. aureus (7). Unexpectedly, neither PMN accumulation in the airways nor sepsis was associated with the increased
mortality of the WT mice. Several reports have documented that
DCs and macrophages are highly sensitive to the effects of the
type I IFNs. Consistent with our findings, in the absence of type
I IFNs, recruited DCs are retained within the lung (34) and there
is a failure to prime macrophages to secrete TNF-α (35). Exactly
which component of the IFN-β cascade activated by S. aureus is
directly responsible for the increased mortality observed in the
mouse model is not yet known but could represent a target for
therapeutic intervention.
The central role of the type I IFN in the host defense against
viral infection has been well documented and is implicated in the
pathogenesis of several bacterial infections (16, 23, 36). The many
consequences of this cascade and its importance in linking the
innate and adaptive immune response are the subject of numerous reviews (12, 22). Exactly how bacterial products activate type I
signaling remains to be established for most pathogens. Nor is
it clear whether the type I IFN responses are beneficial for the
host or the pathogen. TLR4 signaling initiated by LPS is clearly a
major activator of type I IFNs; both IFN-β– and Tyk2-null mice
are resistant to endotoxemia (21). In the case of Bacillus anthracis,
type I IFN signaling also appears to convey a protective response
to the host. For other Gram-positive pathogens, Streptococcus
pneumoniae and Group B streptococci, induction of type I signaling was important for bacterial clearance, and in these studies,
in contrast with our findings, Ifnar–/– mice had persistent bacteremia and could not control the infection (35). More recent
studies suggest that Group B streptococcus DNA is responsible
for induction of type I IFN in mouse macrophages, although the
proximal portions of this signaling system and the specific receptors involved have yet to be identified (36).
Our data indicate that S. aureus similarly activates type I IFNs
and that this has a detrimental effect on the ability of the host
to handle S. aureus pulmonary infection. The local induction
of type I IFN in response to influenza similarly might create
a milieu conducive to staphylococcal superinfection, a major
cause of postinfluenza mortality (37). While we have not identified all of the components of the pathway, S. aureus protein A,
which interacts with several eukaryotic receptors, is the ligand
involved. Moreover, the heterogeneous Xr region or SSR of pro-

tein A is required for type I IFN activation. As the Xr region is
a site of active mutation, it is tempting to speculate that the
impetus for deletion and duplication in the Xr domain is in
some ways related to the immune pressure exerted by type I IFN
effectors. Activation of type I IFNs in the lung enhances susceptibility to S. aureus infection, and this well-characterized pathway could provide an attractive target for immunomodulatory
therapy for pneumonia.
Methods
Bacteria and recombinant proteins. S. aureus 6390, USA300, and clinical isolates were grown in Casamino Acids–yeast extract–glycerophosphate
(CYGP) broth, and E. coli was grown in Luria-Bertaini (LB) broth. The spa
deletion mutant was generated with in-frame deletion of the target gene
by allelic replacement, using the temperature-sensitive plasmid pMAD.
USA300 is erythromycin resistant; therefore, we built a modified pMAD
vector by cloning the kanamycin resistance gene from pFOU into the NaeI
site of pMAD. In brief, about 1 kb PCR products upstream and downstream of targeted sequences were generated and ligated by gene splicing
by overlap extension. The resulting 2-kb product was digested, gel purified,
cloned into pMAD using the same restriction sites, and transformed into
E. coli. Colony PCR was performed on E. coli transformants. Plasmids from
positive clones were verified by digestion analysis and then used to transform S. aureus RN4220, selecting for kanamycin-resistant and blue colonies at 30°C. Plasmid from RN4220 was sequenced and used to transform
S. aureus strain USA300, for which the gene was to be deleted. The process of allelic replacement was described previously (38). Chromosomal
deletion was verified by PCR and DNA sequencing. The resulting deletion
strain was devoid of all protein A sequence and exhibited growth characteristics similar to those of the parental strain.
The full-length spa and the fragment encoding the C-terminal region
of SpA (SpA Xr) from S. aureus Newman have been previously cloned
into pGEX-KG (39). Glutathione-S-transferase (GST) fusion recombinant proteins harboring 1 and 8 SSRs were similarly generated by
cloning the C-terminal region of SpA from clinical isolates (spa type
515 and 131, respectively; Supplemental Table 1) into pGEX-KG. For
expression of recombinant SpA or SpA Xr, overnight cultures of E. coli
BL21 containing the p-GEX-KG–SpA constructs were inoculated into
fresh medium and grown to an OD600 of 0.5. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a concentration of 1 mM, and the
culture was grown for a further 6 hours. Cells were harvested by centrifugation at 8,000 g for 10 minutes in a Sorvall GS-3 rotor. The pellet was
resuspended in PBS containing protease inhibitors (Roche), lysozyme
(200 μg/ml), and DNase I (3 μg/ml). Cells were lysed by repeated freeze/
thaw cycles. Cell debris was removed by centrifugation. Recombinant
proteins expressed from pGEX-KG contained an N-terminal GST fusion
of 26 kDa. The GST fusion proteins were purified using the MicroSpin
GST purification module (Amersham Biosciences; GE Healthcare) and
dialyzed against PBS.
Cell lines and primary cultures. 1HAEo– and 16HBE, human airway epithelial cell lines (D. Gruenert, California Pacific Medical Center Research
Institute, San Francisco, California, USA), were grown as previously
detailed (40, 41). Primary small airway epithelial cells (SAEC; Lonza)
were grown in a polarized fashion on semipermeable supports and used
between passage 2 and 3. Mouse airway epithelial cells, which have very
low endogenous activation of STATs, were used throughout the study
unless indicated. Cells were isolated from the nasal septum from indicated strains of adult mice and grown in primary culture in a polarized
fashion as previously described (42). trif –/– mice were a gift of Ira Tabas
at Columbia University.
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The effect of biochemical inhibitors was tested by pretreating the cells
for 30 minutes with dynasore (80 μM, synthesized by H. Pelish and provided by T. Kirchhausen, Harvard University, Boston, Massachusetts, USA),
25 μM JAK inhibitor I (Pan JAK inhibitor, Calbiochem), 50 μM JAK2
inhibitor (Calbiochem), and 20 μM STAT3 inhibitor (Calbiochem). During stimulation, inhibitors were replenished in the medium. To block the
effects of contaminating LPS, recombinant proteins were incubated with
polymixin B sulfate (50 μg/ml; Sigma-Aldrich) for 1 hour prior to stimulation. For depletion of IFN-β and IL-6, respective neutralizing antibodies
were used at 2 × 104 U/ml (R&D Systems).
Internalization studies. For flow cytometry, cells were incubated with
Alexa Fluor 488–conjugated full-length protein A (Molecular Probes;
Invitrogen) or Alexa Fluor 488–conjugated SpA Xr (Protein Labeling Kit; Molecular Probes, Invitrogen) for various periods of time at
37°C or 4°C. Cells were washed 3 times and trypsin added for 30 minutes to remove surface-bound protein A. Cells were washed, and the
remaining intracellular fluorescence was measured by flow cytometry
(FACSCalibur, BD). For confocal microscopy, 16HBE cells were grown on
Transwell-Clear filters (Costar; Corning) with an air-liquid interface to
form polarized monolayers. Cells were incubated with Alexa Fluor 488–
conjugated protein A (Molecular Probes; Invitrogen) and Alexa Fluor
546–conjugated transferrin (Molecular Probes; Invitrogen) for 1 hour.
After washing, cells were fixed with 4% paraformaldehyde, and filters
were removed from wells and mounted with VECTASHIELD (Vector
Laboratories) onto glass slides.
β-lactamase TEM-1 reporter assay. GST-SpA was cloned into the pCX241
vector, and the resulting GST-SpA–TEM-1 fusion protein was purified
as described above and used to stimulate airway epithelial cells. At different time points (30 minutes; 1, 2, 3, and 4 hours) cells were loaded with
CCF2/AM (Invitrogen) and the percentage of blue fluorescent cells was
determined by microscopy. Fluorescence was also quantified using a fluorescence reader as previously described (26).
Real-time PCR. RNA was isolated using the QIAGEN RNeasy Mini
Kit and subjected to DNase treatment per the manufacturer’s instructions (QIAGEN). cDNA was made from 1 μg of RNA using the iScript
Synthesis Kit (Bio-Rad). For quantitative real-time PCR, amplification
was performed with Power SYBR Green Master Mix in a Step One Plus
Thermal Cycler (Applied Biosystems). The following primers were used
for amplification: mouse IFN-β, 5′-AGACTATTGTTGTACGTCTCC3′ and 5′-CAGTAATAGCTCTTCAAGTGG-3′; mouse Mx-1, 5′-TGTGCAGGCACTATGAGGAG-3′ and 5′-ACTCTGGTCCCCAATGACAG-3′;
mouse PKR, 5′-GCACCGGGTTTTGTATCGA-3′ and 5′-GGAGCACGAAGTACAAGCGC-3′; mouse IL-6, 5′-TGATGCACTTGCAGAAAACAA-3′ and 5′-GGTCTTGGTCCTTAGCCACTC-3′; mouse LIF,
5′-TCTTCCCATCACCCCTGTAAATG-3′ and CTTGATCTGGTTCATGAGGTTGC-3′; mouse actin, 5′-CCTTTGAAAAGAAATTTGTCC-3′
and 5′-AGAAACCAGAACTGAAACTGG-3′; human IFN-β, 5′-CTTGGATTCCTACAAAGAAGC-3′ and 5′-CATCTCATAGATGGTCAATGC-3′;
human IL-6, 5′-AAGAGTAACATGTGTGAAAGC-3′ and 5′-CTACTCTCAAATCTGTTCTGG-3′; and human actin, 5′-GTGGGGCGCCCCAGGCACCA-3′ and 5′-CGGTTGGCCTTGGGGTTCAGGGGGG-3′. Forty
cycles were run with denaturation at 95°C for 15 seconds, annealing at
55°C for 30 seconds, and extension at 60°C for 45 seconds. β-Actin was
used as control for standardization.
Intracellular expression of protein A. 1HAEo– cells were transfected by
nucleofection according to manufacturers instructions (Amaxa) with
a pCMV-FLAG vector encoding FLAG fusions of full-length SpA, the
N-terminal region of SpA (containing the 5 IgG-binding domains) or the
C-terminal region of SpA (SpA Xr). For confocal microscopy, 48 hours
after transfection, cells were fixed with 4% paraformaldehyde, permeabi

lized with 0.3% Triton X-100, and stained for FLAG and phospho-STAT3
(Ser727; Cell Signaling Technology).
Western blot. Cells were lysed using 60 mM n-octyl-β-D-glucopyranoside
in TBS (0.1 M Tris-HCl, 0.15 M NaCl, pH 7.8) containing Complete Mini
Protease Inhibitor Tablets (Roche), 1 mM sodium orthovanadate, 100 mM
sodium fluoride, and 20 μM GM6001. Proteins were separated on 4%–12%
Bis-Tris NuPAGE gels (Invitrogen), transferred to PVDF Immobilon-P
Membrane (Millipore), and blocked with 5% milk in TBST (Tris-buffered
saline plus Tween) (50 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween) for
1 hour at room temperature. Immunodetection was performed using
p-STAT1 (Y701; Cell Signaling Technology), p-STAT2 (Y689; Millipore),
p-STAT3 (Y705; Cell Signaling Technology), STAT1 (Cell Signaling Technology), STAT2 (rabbit polyclonal obtained from C. Schindler at Columbia University), STAT3 (Cell Signaling Technology), and β-actin (SigmaAldrich) antibodies followed by secondary antibodies conjugated to
horseradish peroxidase (Santa Cruz Biotechnology Inc.).
IL-6 detection. 1HAEo– cells, weaned from serum for 24 hours, or mouse
primary airway epithelial cells were exposed to the stimulus indicated,
and IL-6 in the supernatant was measured by ELISA. IL-6 antibody pairs
(Pierce Endogen; Thermo Scientific) were used for detection of human
IL-6 (1HAEo– cells), and IL-6 DuoSet (R&D Systems) was used for detection of mouse IL-6.
Mouse studies. C57BL/6 mice (7 to 10 days old) were intranasally inoculated with 10 μl of S. aureus (108 CFUs), an S. aureus protein A–null strain
(108 CFUs) (43), the C-terminal region of SpA (SpA Xr, 50 μM), or PBS
(control). 6- to 8-week-old Ifnar–/– or 129/SvEV mice were anesthetized
with 100 mg/kg ketamine and 5 mg/kg xylazine and intranasally inoculated with 107 or 108 CFUs S. aureus strain USA300. Mice were sacrificed
at 24 hours after bacterial infection by overdose of pentobarbital. BAL
fluids were obtained by instillation of 3 × 1 ml HBSS into the trachea
of euthanized animals and centrifugation at 180 g for 10 minutes. For
immune cell identification, cell suspensions were obtained from lung
homogenates or BAL fluid and red cells were lysed. Remaining cells were
suspended in PBS containing 10% normal mouse serum and incubated
for 30 minutes at 37°C. Cells were then stained with combinations of
PE-labeled anti-CD45, FITC-labeled anti-Ly6G (BD Biosciences —
Pharmingen), PE-Cy5.5–labeled anti-CD11b (eBioscience), and APClabeled anti-CD11c (eBioscience) in the presence of mouse Fc block
(2.4G2; BD Biosciences — Pharmingen) and normal mouse serum. Negative control samples were incubated with irrelevant, isotype-matched
antibodies. Cells were gated based on their forward scatter/side scatter
profile and analyzed for the double expression of CD45 and Ly6G for
PMNs. DCs were identified by double staining for CD11c and CD11b
within the CD45+ population. For IFN-β and IL-6 mRNA quantification,
mouse lungs were obtained at 16–18 hours after inoculation and stored
in RNAlater (QIAGEN). Bacterial counts in lungs and spleens were determined by plating serial dilutions on CYGP-agar plates. IL-6 and TNF-α in
the BAL fluid were detected by sandwich ELISA (R&D Systems and eBioscience, respectively). All animal studies were approved by the Institute
of Comparative Medicine at Columbia University.
Immunofluorescence staining of mouse lung sections. Mouse lungs were
inflated with and fixed overnight in 4% paraformaldehyde before
embedding in paraffin. 5 μM serial sections were deparaffinized in
xylenes, rehydrated, subjected to antigen retrieval, permeabilized in
0.3% Triton X-100, and blocked in 5% normal goat serum before staining with antibodies to p-STAT3 (S727) or total STAT3. Primary antibodies were revealed by Alexa Fluor 647–conjugated secondary antibodies
(Invitrogen). Imaging was performed on a Zeiss LSM 510 META scanning confocal microscope and analyzed using LSM Image Browser software (version 4.2).

The Journal of Clinical Investigation

http://www.jci.org

research article
Statistics. Samples with normal distribution were analyzed using a 2-tailed
Student’s t test. Samples that did not follow normal distributions were analyzed
with the nonparametric Mann-Whitney test. Mortality studies were subjected
to Fisher’s exact test. P values less than 0.05 were considered significant.
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